Skip to main content

Tretinoin Dosage

Medically reviewed by Drugs.com. Last updated on Jun 13, 2024.

Applies to the following strengths: 10 mg

Usual Adult Dose for Acute Promyelocytic Leukemia

45 mg/m2/day administered as 2 evenly divided doses until complete remission

Duration of therapy: Discontinue therapy 30 days after complete remission or after 90 days of therapy, whichever comes first.

Comments:


Use: For induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RAR alpha gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated.

Usual Pediatric Dose for Acute Promyelocytic Leukemia

1 year and older:
45 mg/m2/day administered as 2 evenly divided doses until complete remission

Duration of therapy: Discontinue therapy 30 days after complete remission or after 90 days of therapy, whichever comes first.

Comments:


Use: For induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RAR alpha gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNINGS:
EXPERIENCED PHYSICIAN AND INSTITUTION:

RETINOIC ACID-APL SYNDROME:
LEUKOCYTOSIS AT PRESENTATION AND RAPIDLY EVOLVING LEUKOCYTOSIS DURING THERAPY:
TERATOGENIC EFFECTS:

CONTRAINDICATIONS:

Safety and efficacy have not been established in patients younger than 1 year.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Monitoring:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.